Ahmedzai 1983.

Study characteristics
Methods	Randomised, double‐blinded, 2‐period cross‐over study
Participants	34 people (19 (56%) men/15 (44%) women), median age 58 years. All cannabis naive Tumour types: small cell bronchial carcinoma Chemotherapy regimen: 2 x 21‐day cycles. Cyclophosphamide 1 g/m2, doxorubicin 40 mg/m2 and etoposide (VP‐16) 100 mg/m2 day 1; etoposide 100 mg/m2 days 2 and 3; vincristine 2 mg with methotrexate 50 mg/m2 day 10 followed by folinic acid rescue. Cyclophosphamide and doxorubicin given IV bolus; VP‐16 IV over 1‐2 hours Chemotherapy emetogenicity: High
Interventions	Nabilone 2 mg orally twice daily x 3 days, n = 34 Prochlorperazine 10 mg orally 3 times daily x 3 days, n = 34
Outcomes	Episodes and frequency of nausea and vomiting day 1; withdrawal due to adverse effects; withdrawals due to death; participant preference due to adverse effects; incidence of feeling high, euphoria, postural dizziness, dysphoria
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	8/34 (24%) participants withdrew
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Approximately 10 days' washout period. Unclear if paired analysis was performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Double dummy tablet"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double‐blind" and dummy tablet used